123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies

Ageing Research Reviews

Volumn 30, Issue , 2016, Pages 122-133

  Orimo, Satoshi ^a   Yogo, Makiko ^b   Nakamura, Tomohiko ^c   Suzuki, Masahiko ^b   Watanabe, Hirohisa ^d  

^a Public School Teachers   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

Dementia with Lewy bodies; Differential diagnosis; Meta iodobenzylguanidine cardiac scintigraphy; Neurodegenerative parkinsonism; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; PARK4 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; BIOLOGICAL MARKER; RADIOPHARMACEUTICAL AGENT;

ALPHA SYNUCLEINOPATHY; AUTONOMIC DYSFUNCTION; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE DISORDER; AXON; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; DISEASE SEVERITY; FAMILIAL DISEASE; GAUCHER DISEASE; HEART SCINTISCANNING; HISTOLOGY; HUMAN; NERVE DEGENERATION; NEUROIMAGING; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PHENOTYPE; PURE AUTONOMIC FAILURE; REM SLEEP; REVIEW; SHY DRAGER SYNDROME; SLEEP DISORDER; SMELLING DISORDER; STANDARDIZATION; SYMPATHETIC INNERVATION; ANIMAL; DIAGNOSTIC IMAGING; HEART; INNERVATION; PROCEDURES; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ALPHA-SYNUCLEIN; ANIMALS; BIOMARKERS; HEART; HUMANS; NEURODEGENERATIVE DISEASES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 84957700568     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2016.01.001     Document Type: Review

References (123)

1. Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., Rosenthal, A., Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000), 239–252.
2. Adler, C.H., Connor, D.J., Hentz, J.G., Sabbagh, M.N., Caviness, J.N., Shill, H.A., Noble, B., Beach, T.G., Incidental Lewy body disease: clinical comparison to a control cohort. Mov. Disord. 25:5 (2010), 642–646.
3. Amino, T., Orimo, S., Ihoh, Y., Takahashi, A., Uchihara, H., Mizusawa, H., Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 15 (2005), 29–34.
4. Ando, Y., Obayashi, K., Tanaka, Y., Tsuji, T., Uchino, M., Takahashi, M., Ando, M., Radiolabelled meta-iodobenzylguanidine in assessment of autonomic dysfunction. Lancet 343 (1994), 984–985.
5. Baba, M., Nakajo, S., Tu, P.-H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q., Iwatsubo, T., Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152 (1998), 879–884.
6. Beach, T.G., White 3rd, C.L., Hladik, C.L., Sabbagh, M.N., Connor, D.J., Shill, H.A., Sasse, J., Bachalakuri, J., Henry-Watson, J., Akiyama, H., Adler, C.H., Arizona Parkinson's Disease Consortium, Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 117:2 (2009), 169–174.
7. Behnke, S., Hellwig, D., Bürmann, J., Runkel, A., Farmakis, G., Kirsch, C.M., Fassbender, K., Becker, G., Dillmann, U., Spiegel, J., Evaluation of transcranial sonographic findings and MIBG cardiac scintigraphy in the diagnosis of idiopathic Parkinson's disease. Parkinsonism Relat. Disord. 2013:11 (2013), 995–999.
8. Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jasen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003), 197–211.
9. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53 (1999), 1020–1025.
10. Chandra, S., Fornai, F., Kwon, H.-B., Yazdani, U., Atasoy, D., Liu, X., Hammer, R.E., Battaglia, G., German, D.C., Castillo, P.E., Südhof, T.C., Double-knockout mice for α- and β-synucleins: effect on synaptic functions. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 14966–14971.
11. 123I-MIBG. Mol. Med. Rep. 6:6 (2012), 1337–1342.
12. Chung, E.J., Kim, E.G., Kim, M.S., Bae, S.K., Seog, D.H., Oh, S.J., Oh, M., Kim, S.J., Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson's dissease. J. Clin. Neurosci. 18 (2011), 922–925.
13. Courbon, F., Brefel-Courbon, C., Thalamas, C., Alibelli, M.J., Berry, I., Montastruc, J.L., Rascol, O., Senard, J.M., Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord. 18 (2003), 890–897.
14. Dorschner, J., Farmakis, G., Behnke, S., Hellwig, D., Schneider, S., Fassbender, K., Kirsch, C.M., Dillmann, U., Spiegel, J., Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 17 (2011), 372–375.
15. Druschky, A., Hilz, M.J., Platsch, G., Radespiel-Tröger, M., Druschky, K., Kuwert, T., Neundörfer, B., Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 175 (2000), 3–12.
16. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D.S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D., Langston, J.W., Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55 (2004), 174–179.
17. Fujishiro, H., Frigerio, R., Burnett, M., Klos, K.J., Josephs, K.A., Delledonne, A., Parisi, J.E., Ahlskog, J.E., Dickson, D.W., Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord. 23 (2008), 1085–1092.
18. Gai, W.P., Power, J.H.T., Blumbergs, P.C., Blessing, W.W., Multiple-system atrophy: a new α-synuclein disease?. Lancet 352 (1998), 547–548.
19. Galvin, J.E., Lee, V.M., Trojanowski, J.Q., Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58 (2001), 86–90.
20. Giasson, B.I., Covy, J.P., Bonini, N.M., Hurtig, H.I., Farrer, M.J., Farrer, M.J., Trojanowski, J.Q., Van Deerlin, V.M., Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59 (2006), 315–322.
21. Goldstein, D.S., Holmes, C., Cannon, R.O. III, Eisenhofer, G., Kopin, I.J., Sympathetic cardioneuropathy in dysautonomias. New Engl. J. Med. 336 (1997), 696–702.
22. Goldstein, D.S., Imrich, R., Peckham, E., Holmes, C., Lopex, G., Crews, C., Hardy, J., Singleton, A., Hallett, M., Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology 69 (2007), 1580–1584.
23. Goldstein, D.S., Sympathetic neuroimaging. Handbook of Clinical Neurology, 2013, Elsevier, Amsterdam.
24. Goldstein, D.S., Dysautonomia in Parkinson disease. Compr. Physiol. 4:2 (2014), 805–826.
25. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J. Auton. Nerv. Syst. 49 (1994), 81–84.
26. 123I-MIBG uptake in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74:4 (2003), 423–426.
27. 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement. Geriatr. Cogn. Disord. 22:5–6 (2006), 379–384.
28. Hasegawa, K., Stoessl, A.J., Yokoyama, T., Kowa, H., Wszolek, Z.K., Yagishita, S., Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat. Disord. 15 (2009), 300–306.
29. Hattori, T., Orimo, S., Hallett, M., Wu, T., Inaba, A., Azuma, R., Mizusawa, H., Relationship and factor strd ucture in multisystem neurodegeneration in Parkinson's disease. Acta Neurol. Scan. 130:6 (2014), 347–353.
30. Hawkes, C.H., Del Tredici, K., Braak, H., Parkinson's disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33 (2007), 599–614.
31. Hayashi, S., Wakabayashi, K., Ishikawa, A., Nagai, H., Saito, M., Maruyama, M., Takahashi, T., Ozawa, T., Tsuji, S., Takahashi, H., An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord. 15 (2000), 884–888.
32. Henderson, E.B., Kahn, J.K., Corbett, J.R., Jansen, D.E., Pippin, J.J., Kulkarni, P., Ugolini, V., Akers, M.S., Hansen, C., Buja, L.M., Abnormal I-123 meta-iodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 78 (1988), 1192–1199.
33. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J. Auton. Nerv. Syst. 53:2–3 (1995), 23023–23024.
34. Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55 (1992), 181–184.
35. Iijima, M., Osawa, M., Momose, M., Kobayakawa, T., Saito, S., Iwata, M., Uchiyama, S., Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. Mov. Disord. 25 (2010), 1143–1149.
36. Imrich, R., Eldadah, B.A., Bentho, O., Pechnik, S., Sharabi, Y., Holmes, C., Grossman, E., Goldstein, D.S., Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. Parkinsonism Relat. Disord. 15:2 (2009), 122–127.
37. Ishikawa, A., Tsuji, S., Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 47 (1996), 160–166.
38. Itokawa, K., Tamura, N., Kawai, N., Shimazu, K., Ishii, K., Parkinsonism in type I Gaucher's disease. Int. Med. 45:20 (2006), 1165–1167.
39. Jacobson, A.F., Travin, M.I., Impact of medications on mIBG uptake, with specific attention to the heart: comprehensive review of the literature. J. Nucl. Cardiol. 22:5 (2015), 980–993.
40. Janes, R.D., Brandys, J.C., Hopkins, D.A., Johnstone, D.E., Murphy, D.A., Armour, J.A., Anatomy of human extrinsic cardiac nerves and ganglia. Am. J. Cardiol. 57 (1986), 299–309.
41. Kahn, J.K., Sisson, J.C., Vinik, A.I., Prediction of sudden cardiac death in diabetic autonomic neuropathy. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 29:9 (1988), 1605–1606.
42. 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J. Nucl. Med. 47:7 (2006), 1099–1101.
43. Kim, J.S., Lee, K.S., Song, I.U., Kim, Y.I., Kim, S.H., You, I.R., Kim, H.T., Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms. J. Neurol. Sci. 270 (2008), 122–126.
44. 123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism. Mov. Disord. 21:11 (2006), 1990–1994.
45. 123I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study. Arch. Geront. Geriatr. 56:1 (2013), 124–128.
46. Kline, R.C., Swanson, D.P., Wieland, D.M., Thrall, J.H., Gross, M.D., Pitt, B., Beierwaltes, W.H., Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J. Nucl. Med. 22:2 (1981), 129–132.
47. Lebouvier, T., Clairembault, T., Devos, D., Pallardy, A., Coron, E., Neunlist, M., Derkinderen, P., Peripheral autonomic nervous system involvement in Gaucher-related parkinsonism. J. Parkinsons Dis. 4:1 (2014), 29–32.
48. 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 77:3 (2006), 372–374.
49. 123I-MIBG scintigraphy in patients with essential tremor. Mov. Disord. 21:8 (2006), 1235–1238.
50. 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 78:11 (2007), 1250–1252.
51. Li, Y., Sekine, T., Funayama, M., Li, L., Yoshino, H., Nishioka, K., Tomiyama, H., Hattori, N., Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol. Aging 35:4 (2014), e3–8 935.
52. Link, J.M., Caldwell, J.H., Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat. Clin. Pract. Cardiovasc. Med. 5:Suppl 2 (2008), S79–86.
53. 123I]metaiodobenzylguanidine. Diabetes 41:9 (1992), 1069–1075.
54. McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, H., Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., Hardy, J., Iwatsubo, T., Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A., Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y., Molina, J.A., Mukaetova-Ladinska, E.B., Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q., Yamada, M., Consortium on DLB, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005), 1863–1872.
55. 123I-MIBG myocardial scintigraphy in the diagnosis of Lewy body dementia. Neurologia 25:7 (2010), 414–421.
56. Matsui, H., Nishinaka, K., Oda, M., Komatsu, K., Kubori, T., Udaka, F., Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms?. Parkinsonism Relat. Dsiord. 12:5 (2006), 284–288.
57. Miki, Y., Mori, F., Wakabayashi, K., Kuroda, N., Orimo, S., Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov. Disord. 24 (2009), 2299–2301.
58. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 31:5 (2008), 717–723.
59. Miyamoto, T., Miyamoto, M., Iwanami, M., Hirata, K., Idiopathic REM sleep behavior disorder: implications for the Pathogenesis of Lewy Body Diseases. Parkinson's Dis., 2011, 2011, 941268.
60. Mizutani, Y., Nakamura, T., Okada, A., Suzuki, J., Watanabe, H., Hirayama, M., Sobue, G., Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson's disease. Parkinsonism Relat. Disord. 20:5 (2014), 520–524.
61. Mori, K., Iwasaki, Y., Ito, M., Mimuro, M., Yoshida, M., Decreased myocardial uptake of meta-iodobenzylguanidine in an autopsy-confirmed case of corticobasal degeneration with Lewy bodies restricted to the sympathetic ganglia. Clin. Neurol. (in Japanese) 52 (2012), 405–410.
62. Morozumi, T., Ishida, Y., Tani, A., Sato, H., Matsuyama, T., Ozaki, H., Hori, M., Kitabatake, A., Kamada, T., Kimura, K., Clinical significance of I-123 MIBG myocardial scintigraphy for evaluating the severity of congestive heart failure. Kaku Igaku (in Japanese) 28:3 (1991), 271–280.
63. Nagamachi, S., Fujita, S., Nishii, R., Futami, S., Tamura, S., Mizuta, M., Nakazato, M., Kurose, T., Wakamatsu, H., Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J. Nucl. Cardiol. 13:1 (2006), 34–42.
64. 123I-MIBG myocardial scintigraphy in non-insulin-dependent diabetes mellitus. Ann. Nucl. Med. 16:1 (2002), 33–38.
65. Nagayama, H., Hamamoto, M., Ueda, M., Nagashima, J., Katayama, Y., Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76:2 (2005), 249–251.
66. Nagayama, H., Yamazaki, M., Ueda, M., Nishiyama, Y., Hamamoto, M., Katayama, Y., Mori, O., Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology: an autopsy case report. Mov. Disord. 23 (2008), 1055–1057.
67. Nakajima, K., Okuda, K., Matsuo, S., Yoshita, M., Taki, J., Yamada, M., Kinuya, S., Standardization of meta-iodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur. J. Nucl. Med. Mol. Imaging 39 (2012), 113–119.
68. Nakajima, K., Okuda, K., Yoshimura, M., Matsuo, S., Wakabayashi, H., Imanishi, Y., Kinuya, S., Multicenter cross-calibration of I-123 meta-iodobenzylguanidine heart-to mediastinum ratios to overcome camera-collimator variations. J. Nucl. Cardiol. 21 (2014), 970–978.
69. Nakamura, T., Hirayama, M., Ito, H., Takamori, M., Hamada, K., Takeuchi, S., Watanabe, H., Koike, Y., Sobue, G., Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease. J. Neurol. Sci. 263:1–2 (2007), 133–138.
70. Nishioka, K., Hayashi, S., Farrer, M.J., Singleton, A.B., Yoshino, H., Imai, H., Kitami, T., Sato, K., Kuroda, R., Tomiyama, H., Mizoguchi, K., Murata, M., Toda, T., Imoto, I., Inazawa, J., Mizuno, Y., Hattori, N., Clinical heterogeneity of α-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59 (2006), 298–309.
71. 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol. Aging 31:11 (2010), 1903–1911.
72. Nukada, H., Kowa, H., Saitoh, T., Tazaki, Y., Miura, S., A big family of paralysis agitans. Clin. Neurol. (in Japanese) 18 (1978), 627–634.
73. 123I-MIBG uptake reflects cardiac sympathetic dysfunction in de novo Parkinson's disease. J. Neural Transm. 118:9 (2011), 1323–1327.
74. Okuda, K., Nakajima, K., Hosoya, T., Ishikawa, T., Konishi, T., Matsubara, K., Matsuo, S., Kinuya, S., Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac iodine-123 MIBG imaging. J. Nucl. Cardiol. 18 (2011), 82–88.
75. 123I-meta-iodobenzylguanidine cardiac scintigraphy in Parkinson's disease. Igakunoayumi (in Japanese) 179 (1996), 1728–1729.
76. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67 (1999), 189–194.
77. Orimo, S., Oka, T., Miura, H., Tsuchiya, K., Mori, F., Wakabayashi, K., Nagao, T., Yokochi, M., Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 73 (2002), 776–777.
78. 123I] meta-iodobenzylguanidin myocardial scintigraphy differentiates corticobasal degeneration from Parkinson’ disease. Int. Med. 42 (2003), 127–128.
79. Orimo, S., Amino, T., Ito, Y., Takahashi, A., Kojo, T., Uchihara, T., Tsuchiya, K., Mori, F., Wakabayashi, K., Takahashi, H., Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 109 (2005), 583–588.
80. Orimo, S., Amino, T., Yokochi, M., Kojo, T., Uchihara, T., Takahashi, A., Hattori, N., Mizuno, Y., Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord. 20 (2005), 1350–1353.
81. Orimo, S., MIBG myocardial scintigraphy in the early diagnosis of Parkinson's disease. CNS Drugs 21:Special issue (2007), 11–15.
82. Orimo, S., Kanazawa, T., Nakamura, A., Uchihara, T., Mori, F., Kakita, A., Wakabayashi, K., Takahashi, H., Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. 113:1 (2007), 81–86.
83. Orimo, S., Takahashi, A., Uchihara, T., Mori, F., Kakita, A., Wakabayashi, K., Takahashi, H., Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol. 17 (2007), 24–30.
84. Orimo, S., Uchihara, T., Nakamura, A., Mori, F., Kakita, A., Wakabayashi, K., Takahashi, H., Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson disease. Brain 131 (2008), 642–645.
85. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 18 (2012), 949–950.
86. Otsuka, J., Sakamoto, M., Azuma, L., Takahashi, M., Inaba, A., Mizuno, Y., Orimo, S., A study of an effect of diabetes mellitus on cardiac MIBG uptake—investigation in the differential diagnosis of dementia. Clin. Neurol. (in Japanese), 53, 2013, 1551.
87. 123I MIBG) scintigraphic study. Diabetes Care 36:8 (2013), 2395–2401.
88. Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F., Zigmond, M.J., A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22 (2002), 3090–3099.
89. Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A.E., Halliday, G., Goetz, C.G., Gasser, T., Dubois, B., Chan, P., Bloem, B.R., Adler, C.H., Deuschl, G., MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 30 (2015), 1591–1601.
90. 123I-metaiodobenzylguanidine uptake in genetic Parkinson's disease. Mov. Disord. 23 (2008), 21–27.
91. Reinhardt, M.J., Jungling, F.D., Krause, T.M., Braune, S., Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur. J. Nucl. Med. 27:5 (2000), 595–600.
92. 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J. Neurol. Sci. 220:1-2 (2004), 105–111.
93. 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J. Nucl. Med. 40:3 (1999), 371–375.
94. Schofer, J., Spielmann, R., Schuchert, A., Weber, K., Schluter, M., Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 12 (1988), 1252–1258.
95. Singleton, A., Gwinn-Hardy, K., Sharabi, Y., Li, S.T., Holmes, C., Dendi, R., Hardy, J., Singleton, A., Crawley, A., Goldstein, D.S., Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 127 (2004), 768–772.
96. Slaets, S., Van Acker, F., Versijpt, J., Hauth, L., Goeman, J., Martin, J.J., De Deyn, P.P., Engelborghs, S., Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. Int. J. Geriatr. Psychiatry 30:8 (2014), 864–869.
97. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., α-Synuclein in Lewy bodies. Nature 388 (1997), 839–840.
98. 123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report. Mov. Disord. 20:5 (2005), 634–636.
99. Suzuki, M., Urashima, M., Oka, H., Hashimoto, M., Taira, K., Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease. Neuroreport 18 (2007), 1867–1870.
100. Takahashi, H., Ohama, E., Suzuki, S., Horikawa, Y., Ishikawa, A., Morita, T., Tsuji, S., Ikuta, F., Familial juvenile parkinsonism: clinical and pathological study in a family. Neurology 44 (1994), 437–441.
101. Takahashi, M., Azuma, R., Kitazono, H., Inaba, A., Ikemura, M., Oka, T., Uchihara, T., Wakabayashi, K., Kakita, A., Takahashi, H., Yoshida, M., Toru, S., Kobayashi, T., Orimo, S., Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease. J. Neurol. Neurosurg. Psychiatry 86:9 (2015), 939–944.
102. 123I-MIBG scintigraphy in a case of pure progressive autonomic failure. Clin. Neurol. (in Japanese) 33:7 (1993), 784–786.
103. Takatsu, H., Nishida, H., Matsuo, H., Watanabe, S., Nagashima, K., Wada, H., Noda, T., Nishigaki, K., Fujiwara, H., Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 41 (2000), 71–77.
104. Taki, J., Nakajima, K., Hwang, E.-H., Matsunari, I., Komai, K., Yoshita, M., Sakajiri, K., Tonami, N., Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med. 27 (2000), 566–573.
105. Tateno, M., Kobayashi, S., Shirasaka, T., Furukawa, Y., Fujii, K., Morii, H., Yasumura, S., Utsumi, K., Saito, T., Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord. 26:5 (2008), 453–457.
106. Tijero, B., Gomez-Esteban, J.C., Llorens, V., Lezcano, E., Gonzalez-Fernandez, M.C., de Pancorbo, M.M., Ruiz-Martinez, J., Cembellin, J.C., Zarranz, J.J., Cardiac sympathetic denervation precedes nigrostriatal loss in the E46 K mutation of the alpha-synuclein gene (SNCA). Clin. Auton. Res., 20, 2010, 267269.
107. Tomiyama, H., Lesage, S., Tan, E.K., Jeon, B.S., Familial Parkinson's disease/parkinsonism. Biomed. Res. Int., 2015, 2015, 736915.
108. Treglia, G., Cason, E., Stefanelli, A., Cocciolillo, F., Di Giuda, D., Fagioli, G., Giordano, A., MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin. Auton. Res. 22 (2011), 43–55.
109. Treglia, G., Stefanelli, A., Cason, E., Cocciolillo, F., Di Giuda, D., Giordano, A., Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin. Neurol. Neurosurg. 13:10 (2011), 823–829.
110. Treglia, G., Cason, E., Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J. Neuroimaging 22 (2012), 111–117.
111. Treglia, G., Cason, E., Cortelli, P., Gabellini, A., Liguori, R., Bagnato, A., Giordano, A., Fagioli, G.J., Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques?. Neuroimaging 24 (2014), 149–154.
112. 123I-MIBG myocardial scintigraphy and clinical features of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 86:9 (2015), 945–951.
113. Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M., Takahashi, H., NACP a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239 (1997), 45–48.
114. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 70 (2001), 781–783.
115. Yoritaka, A., Shimo, Y., Shimo, Y., Inoue, Y., Yoshino, H., Hattori, N., Nonmotor symptoms in patients with PARK2 mutations. Parkinson's Dis., 13, 2011, 473640.
116. 123I-meta-iodobenzyl-guanidine cardiac scintigraphy in Parkinson's disease. Sinkeinaika (in Japanese) 45 (1996), 221–225.
117. Yoshita, M., Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci. 155 (1998), 60–67.
118. 123I] MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 71 (2001), 583–588.
119. 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:12 (2006), 1850–1854.
120. 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One, 10(3), 2015, e0120540.
121. 123I-MIBG) scintigraphy parameter predicts cardiac and cerebrovascular events in type 2 diabetic patients without structural heart disease. Circ. J. 76:2 (2012), 399–404.
122. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Muñoz, D.G., de Yebenes, J.G., The new mutation E46 K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004), 164–173.
123. Zarranz, J.J., Fernandez-Bedoya, A., Lambarri, I., Gomez-Esteban, J.C., Lezcano, E., Zamacona, J., Madoz, P., Abnormal sleep architecture is an early feature in the E46 K familial synucleinopathy. Mov. Disord. 20 (2005), 1310–1315.